arsenic has been researched along with clofarabine in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Craig, CM; Schiller, GJ | 1 |
| Burnett, AK; Hills, RK | 1 |
1 review(s) available for arsenic and clofarabine
| Article | Year |
|---|---|
Acute myeloid leukemia in the elderly: conventional and novel treatment approaches.
Topics: Adenine Nucleotides; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antineoplastic Agents; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Azacitidine; Clofarabine; Cytarabine; Hematopoietic Stem Cell Transplantation; Humans; Hydrazines; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Oxides; Recurrence; Sulfonamides | 2008 |
1 other study(ies) available for arsenic and clofarabine
| Article | Year |
|---|---|
Applicability of a "Pick a Winner" trial design to acute myeloid leukemia.
Topics: Adenine Nucleotides; Aged; Aminoglycosides; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Arabinonucleosides; Arsenic Trioxide; Arsenicals; Clinical Trials, Phase III as Topic; Clofarabine; Cost-Benefit Analysis; Cytarabine; Cytosine; Drug Discovery; Early Termination of Clinical Trials; Follow-Up Studies; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Middle Aged; Multicenter Studies as Topic; Oxides; Patient Selection; Quality-Adjusted Life Years; Quinolones; Randomized Controlled Trials as Topic; Research Design; Sample Size; Software Design; Treatment Outcome; United Kingdom | 2011 |